Earlier Cancer Detection.

Reliable Results.

Proactive screening to keep living your best life with earlier multi-cancer detection.*

*The EPISEEK™ test may not identify signals for every type of cancer at every stage. There is a possibility of false positive and false negative results.

The EPISEEK™ Test

EPISEEK™ is a cutting-edge multi-cancer detection (MCD) test that uses a simple blood draw to identify DNA changes linked to over 60 types of cancer. By detecting hypermethylated DNA loci—i.e., regions consistently altered across multiple cancer types—EPISEEK™ provides reliable, early detection, even before symptoms appear.

LEARN MORE

Brain

Lung & Bronchus

Breast

Colon & Rectum

Stomach

Prostate

Bladder

Kidney

Pancreas

Uterine and Cervical

Lymphoma

Myeloma & Leukemia

Thyroid

Oral

Liver

Esophagus

Ovarian

Skin

How It Works

EPISEEK™ redefines cancer detection and monitoring, identifying cancer with more specificity than imaging and by being more accessible than invasive tissue biopsies.

Provider Draws Blood

Test Is Sent to Lab

Specimen Is Analyzed

Provider Explains Results

Results in Just 7–10 Days

LEARN MORE

Who Is EPISEEK™ For?

The EPISEEK™ test is recommended for the following :

R

Individuals at Higher Risk

Those with a personal or family history of cancer
Individuals with lifestyle or environmental exposures that increase risk (e.g., firefighters)

R

Health-Conscious Individuals

People who prioritize preventive health care and want to take proactive steps to monitor their health

R

Individuals Aged 45 or Older

R

Healthcare Providers

Physicians, oncologists, and general practitioners seeking advanced diagnostic tools to offer their patients
Clinics and hospitals that want to integrate cutting-edge cancer screening into their services

R

Employers or Wellness Programs

Organizations aiming to enhance employee health benefits by providing access to advanced health screenings

R

Researchers and Institutions

Institutions interested in leveraging innovation technologies for further studies in early cancer detection

The EPISEEK™ test is not recommended for the following:

Individuals who are pregnant
Individuals aged 21 years or younger
Individuals undergoing active cancer treatment or those with an active known malignancy

Talk to your healthcare provider about including the EPISEEK™ test as part of your annual checkup!

The Right Provider Is Committed to Keeping You Healthy

“As a physician, I know that early detection is critical in the fight against cancer. The EPISEEK™ liquid biopsy test is a groundbreaking tool that identifies cancer at its earliest stages, when it’s most treatable. I highly recommend Precision Epigenomics for its accuracy and its potential to save lives by catching cancer before symptoms begin. Not only do I order EPISEEK™ for my patients, but my healthcare provider also ordered it for me.”

— Kristine Romine, MD

“I use EPISEEK™ alongside standard guideline-based cancer screenings for my patients. It offers exceptional specificity and is an excellent tool for early detection. EPISEEK™ screens for the top 10 leading causes of cancer-related deaths, including brain cancer, and is available at a more accessible price point than alternatives. It’s a great choice for my patients to help with early detection of cancer.”

— Carl Seger, MD

“When I received my EPISEEK™ results showing no cancer signals, it felt like a weight had been lifted. Adding this test to my regular screenings gives me confidence that I’m doing everything I can to protect my health. That peace of mind is priceless. I encourage anyone thinking about additional screening to take that step—you won’t regret it.”